Our findings also demonstrate the ability of HDAC inhibitors to treat AML, particularly AML expressing low levels of RNF5, and provides a method to stratify AML patients for treatment with HDAC inhibitors. This evidence concerns the gene RNF5 and acute myeloid leukemia.